Apalutamide and Avanafil: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A induction may reduce avanafil exposure and therapeutic effect.
Clinical significance and safety
Apalutamide and Avanafil: The avanafil label does not recommend concurrent CYP3A inducers because effectiveness may decrease. Do not increase avanafil yourself. The prescriber should consider an alternative or review treatment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.